CLINICAL RESEARCH Interventional Cardiology Value of Platelet Reactivity in Predicting Response to Treatment and Clinical Outcome in Patients Undergoing Primary Coronary Intervention Insights Into the STRATEGY Study

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study.

  2005cited by this paper
• CLINICAL RESEARCH Interventional Cardiology Stent Thrombosis Is Associated With an Impaired Response to Antiplatelet Therapy

  2005cited by this paper
• Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis: a case-control study.

  2005cited by this paper
• Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting.

  2005cited by this paper
• Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial.

  2005cited by this paper
• Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment.

  2005cited by this paper
• High-Dose BoluS TiRofibAn and Sirolimus Eluting STEnt versus Abiciximab and Bare Metal Stent in Acute MYocardial Infarction (STRATEGY) Study—Protocol Design and Demography of the First 100 Patients

  2004cited by this paper
• Platelet Function Predicts Myocardial Damage in Patients With Acute Myocardial Infarction

  2004cited by this paper
• A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction.

  2003cited by this paper
• A preferred reperfusion strategy for acute myocardial infarction.

  2003cited by this paper
• Clopidogrel for Coronary Stenting Response Variability, Drug Resistance, and the Effect of Pretreatment Platelet Reactivity

  2003cited by this paper
• Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials.

  2002cited by this paper
• Determination of platelet aggregation inhibition during percutaneous coronary intervention with the platelet function analyzer PFA-100.

  2002cited by this paper
• Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention.

  2001cited by this paper
• Point-of-Care Measured Platelet Inhibition Correlates With a Reduced Risk of an Adverse Cardiac Event After Percutaneous Coronary Intervention: Results of the GOLD (AU-Assessing Ultegra) Multicenter Study

  2001cited by this paper
• Platelet Reactivity Characterized Prospectively: A Determinant of Outcome 90 Days After Percutaneous Coronary Intervention

  2001cited by this paper
• Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction.

  2000cited by this paper
• Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle Myocardial Infarction Study Group.

  1998cited by this paper
• PFA-100™ System: A New Method for Assessment of Platelet Dysfunction

  1998cited by this paper
• Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.

  1998cited by this paper
• TIMI frame count: a quantitative method of assessing coronary artery flow.

  1996cited by this paper
• The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings.

  1985cited by this paper
• The thrombolysis in myocardial infarction (TIMI) trial.

  1985cited by this paper

• Serial Examination of Platelet Function Tests Might Predict Prognosis of Patients with Acute Ischemic Stroke—A Cohort Study

  2024cites this paper
• Clinical pharmacology of selatogrel for self-administration by patients with suspected acute myocardial infarction

  2023cites this paper
• Primary Percutaneous Coronary Intervention with High-Bolus Dose Tirofiban: The FASTER (Favorite Approach to Safe and Effective Treatment for Early Reperfusion) Multicenter Registry

  2022cites this paper
• 13 (2) January 2021 CVJ.pmd

  2021cites this paper
• Pharmacokinetic/pharmacodynamic modeling of drug interactions at the P2Y12 receptor between selatogrel and oral P2Y12 antagonists

  2021cites this paper
• Myocardial preservation during primary percutaneous intervention: It's time to rethink?

  2021cites this paper
• Crushed/chewed administration of potent P2Y12 inhibitors in ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: Systematic review and meta-analysis

  2021cites this paper
• Plasma calprotectin was associated with platelet activation and no-reflow phenomenon in acute coronary syndrome

  2020cites this paper
• Invasive treatment of coronary artery disease

  2020cites this paper
• Effect of Prehospital Crushed Prasugrel Tablets in Patients With ST-Segment-Elevation Myocardial Infarction Planned for Primary Percutaneous Coronary Intervention: The Randomized COMPARE CRUSH Trial.

  2020cites this paper
• Over time relationship between platelet reactivity, myocardial injury and mortality in patients with SARS-CoV-2-associated respiratory failure

  2020cites this paper
• Effect of Prehospital Crushed Prasugrel Tablets in Patients With ST-Segment–Elevation Myocardial Infarction Planned for Primary Percutaneous Coronary Intervention

  2020cites this paper
• Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment–Elevation Myocardial Infarction

  2020cites this paper
• Primary Angioplasty: From the Artery to the Myocardium

  2020cites this paper
• Impaired platelet reactivity in patients with septic shock: a proof-of-concept study

  2020cites this paper
• Cangrelor versus Ticagrelor in Patients Treated with Primary Percutaneous Coronary Intervention: Impact on Platelet Activity, Myocardial Microvascular Function and Infarct Size: A Randomized Controlled Trial

  2019cites this paper
• Short-term efficacy of ticagrelor in acute ST-segment elevation myocardial infarction patients undergoing an emergency percutaneous coronary intervention

  2019cites this paper
• Hematological Parameters Outperform Plasma Markers in Predicting Long-Term Mortality After Coronary Angiography

  2018cites this paper
• Safety of Ticagrelor Compared to Clopidogrel after Prehospital Initiation of Treatment

  2018cites this paper
• ANTIPLATELET ADEQUACY OF CYCLOPENTYL TRIAZOLOPYRIMIDINE VERSUS CLOPIDOGREL IN-PATIENTS WITH CORONARY HEART DISEASE

  2018cites this paper
• The no-reflow phenomenon: mechanisms and therapeutic targets

  2018cites this paper
• Peri-Procedural Platelet Reactivity in Percutaneous Coronary Intervention

  2018cites this paper
• Outcome of Triple Antiplatelet Therapy Including Cilostazol in Elderly Patients with ST-Elevation Myocardial Infarction who Underwent Primary Percutaneous Coronary Intervention: Results from the INTERSTELLAR Registry

  2017cites this paper
• How Long Does It Take for Clopidogrel and Ticagrelor to Inhibit Platelets in Patients Undergoing Primary Percutaneous Coronary Intervention? A Detailed Pharmacodynamic Analysis: Time Course of Platelet Reactivity in STEMI (TOPS)

  2017cites this paper
• Comparison of Angioplasty With Infusion ofTirofibanorAbciximabandWithImplantation of Sirolimus-Eluting or Uncoated Stents for Acute Myocardial Infarction

  2017cites this paper
• Unmet goals in the treatment of Acute Myocardial Infarction: Review

  2017cites this paper
• Predictors and Outcomes of No-Reflow Phenomenon Following Primary Percutaneous Intervention for ST Elevation Myocardial Infarction

  2017cites this paper
• Effect of supplementation of lecithin and carnitine on growth performance and nutrient digestibility in pigs fed high-fat diet

  2017cites this paper
• Impact of platelet inhibition level on subsequent no-reflow in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.

  2017cites this paper
• Outcome after percutaneous coronary intervention for different indications: long-term results from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).

  2016cites this paper
• Cardioprotective effects of intracoronary administration of 4-chlorodiazepam in small and large animal models of ischemia-reperfusion.

  2016cites this paper
• Effect of Elevated Reperfusion Pressure on “No Reflow” Area and Infarct Size in a Porcine Model of Ischemia–Reperfusion

  2016cites this paper
• Aspirin dosing frequency in the primary and secondary prevention of cardiovascular events

  2016cites this paper
• Immediate response to prasugrel loading in patients with ST-elevation myocardial infarction: Predictors and outcome.

  2016cites this paper
• Percutaneous Coronary Interventions in Stable and Acute Coronary Syndromes: Stent technology, lesion complexity and clinical outcome

  2015influential citation
• Vascular risk levels affect the predictive value of platelet reactivity for the occurrence of MACE in patients on clopidogrel

  2015cites this paper
• Intrinsic platelet reactivity before start with clopidogrel as predictor for on-clopidogrel platelet function and long-term clinical outcome

  2015cites this paper
• Aspirin ‘Resistance': Impact on No-Reflow, Platelet and Inflammatory Biomarkers in Diabetics after ST-Segment Elevation Myocardial Infarction

  2015cites this paper
• Platelet aggregation values in patients with cardiovascular risk factors are reduced by verbascoside treatment. A randomized study.

  2015cites this paper
• Ticagrelor overcomes high platelet reactivity in patients with acute myocardial infarction or coronary artery in-stent restenosis: a randomized controlled trial

  2015cites this paper
• Stent thrombosis in new-generation drug-eluting stents in patients with STEMI undergoing primary PCI: a report from SCAAR.

  2014cites this paper
• ST segment resolution after thrombolytic therapy for acute myocardial infarction

  2014cites this paper
• The conundrum of antithrombotic drugs before, during and after primary PCI.

  2014cites this paper
• CMD in Obstructive CAD

  2014cites this paper
• Outcome Comparison of 600 mg versus 300 mg Loading dose of Clopidogrel for Patients with ST-Elevation Myocardial Infarction: A Meta-Analysis

  2014cites this paper
• Impact of initial clinical presentation on clopidogrel low response.

  2013cites this paper
• Bimodal response to aspirin loading in acute ST-elevation myocardial infarction

  2013cites this paper
• Thrombozytenaktivierung im akuten Koronarsyndrom gemessen mittels Platelet Adhesion Assay

  2013cites this paper
• Effect of Statin Pretreatment on Myocardial Perfusion in Patients Undergoing Primary Percutaneous Coronary Intervention: A Systematic Review and Meta‐analysis

  2013cites this paper
• Platelet function tests in clinical cardiology: unfulfilled expectations.

  2013influential citation
• High post-clopidogrel platelet reactivity assessed by a point-of-care assay predicts long-term clinical outcomes in patients with ST-segment elevation myocardial infarction who underwent primary coronary stenting.

  2013cites this paper
• Rationale and design of the on-treatment PLAtelet Reactivity-Guided Therapy Modification FOR ST-Segment Elevation Myocardial Infarction (PLATFORM) randomized trial.

  2013cites this paper
• Impact of high post-loading platelet aggregation on 30-day clinical outcomes after primary percutaneous coronary intervention. The antiplatelet regimen tailoring after primary PCI (ART-PCI) trial.

  2013cites this paper
• Intrinsic platelet reactivity and thrombus burden in patients with ST-elevation myocardial infarction.

  2013cites this paper
• Detecting Baseline Platelet Hyperreactivity ( Prothrombotic Status ) and Cardiac Risk

  2013influential citation
• Myocardial 'no-reflow'--diagnosis, pathophysiology and treatment.

  2013cites this paper
• Randomized comparison of new dual-antiplatelet therapy (aspirin, prasugrel) and triple-antiplatelet therapy (aspirin, clopidogrel, cilostazol) using P2Y12 point-of-care assay in patients with STEMI undergoing primary PCI.

  2013cites this paper
• P2Y12 inhibitors adjunctive to primary PCI therapy in STEMI: fighting against the activated platelets.

  2013cites this paper
• Soluble CD40 ligand release in patients with stable coronary artery disease during elective stent implantation: effect of drug-eluting stent over bare metal stent.

  2013cites this paper
• Antiplatelet effect of thienopyridine (clopidogrel or prasugrel) pretreatment in patients undergoing primary percutaneous intervention for ST elevation myocardial infarction.

  2013cites this paper
• Prasugrel Versus High Dose Clopidogrel to Overcome Early High on Clopidogrel Platelet Reactivity in Patients with ST Elevation Myocardial Infarction

  2012cites this paper
• Assessment of platelet function in patients on antiplatelet therapy undergoing cardiac surgery: a review.

  2012cites this paper
• The in vitro effects of verbascoside on human platelet aggregation

  2012cites this paper
• Antiplatelet effect of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an analysis of the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Myocardial

  2012cites this paper
• Randomized Assessment of Ticagrelor Versus Prasugrel Antiplatelet Effects in Patients with ST-Segment–Elevation Myocardial Infarction

  2012cites this paper
• Coronary no reflow.

  2012cites this paper
• A contemporary viewpoint on ‘aspirin resistance’

  2012cites this paper
• Effects of prasugrel on platelet inhibition during systemic endotoxaemia: a randomized controlled trial.

  2012cites this paper
• Predictors of high on-treatment platelet reactivity early after clopidogrel loading in ST-elevation myocardial infarction.

  2012cites this paper
• Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients wit

  2012cites this paper
• Polymorphism in the protease‐activated receptor‐4 gene region associates with platelet activation and perioperative myocardial injury

  2012cites this paper
• Use of the platelet function analyser PFA-100™ in juvenile pigs

  2012cites this paper
• Wysoka reaktywność płytek krwi w czasie reperfuzji — nowy czynnik ryzyka zjawiska no reflow?

  2012cites this paper
• Managing no-reflow during percutaneous coronary intervention

  2012cites this paper
• Prophylaxis and treatment of microvascular obstruction in percutaneous coronary intervention

  2012cites this paper
• Outcome comparison of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results from the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Myocardial Inf

  2011cites this paper
• Residual platelet reactivity after aspirin and clopidogrel treatment predicts 2-year major cardiovascular events in patients undergoing percutaneous coronary intervention.

  2011cites this paper
• The relationship between platelet reactivity and infarct-related artery patency in patients presenting with a ST-elevation myocardial infarction

  2011cites this paper
• The in vitro effect of the new antithrombotic drug candidate ALX-0081 on blood samples of patients undergoing percutaneous coronary intervention

  2011cites this paper
• Gene expression profiling in peripheral blood nuclear cells in patients with refractory ischaemic end-stage heart failure

  2011cites this paper
• Incomplete inhibition of platelet function as assessed by the platelet function analyzer (PFA-100) identifies a subset of cardiovascular patients with high residual platelet response while on aspirin

  2011cites this paper
• Monitoring Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention

  2011cites this paper
• Triple Antiplatelet Therapy in Acute Coronary Syndromes

  2011cites this paper
• Low stent thrombosis risk with the XIENCE V® Everolimus-Eluting Coronary Stent: evidence from randomized and single-arm clinical trials.

  2011cites this paper
• Residual platelet reactivity after clopidogrel loading in patients with ST-elevation myocardial infarction undergoing an unexpectedly delayed primary percutaneous coronary intervention. - Impact on intracoronary thrombus burden and myocardial perfusion-.

  2011cites this paper
• Glycoprotein IIb/IIIa inhibitors: an update on the mechanism of action and use of functional testing methods to assess antiplatelet efficacy.

  2011cites this paper
• Personalised Medicine in New Zealand: A new approach to healthcare delivery

  2011cites this paper
• Resistance to aspirin and clopidogrel therapy

  2011cites this paper
• Clinical and prognostic implications of the initial response to aspirin in patients with acute coronary syndrome.

  2011cites this paper
• Upstream tirofiban reduces reperfusion cardiac arrhythmias in patients of acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.

  2011cites this paper
• Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy.

  2010cites this paper
• Effects of aspirin and NO-aspirin (NCX 4016) on platelet function and coagulation in human endotoxemia

  2010cites this paper
• Contemporary platelet function testing

  2010cites this paper
• Platelet hyperfunction is decreased by additional aspirin loading in patients presenting with myocardial infarction on daily aspirin therapy

  2010cites this paper
• [Urgent percutaneous coronary intervention leads to a decrease in serum concentrations of soluble CD40 ligand].

  2010cites this paper
• Tailored Medical and Interventional Therapy Against Recurrent Stent Thrombosis After Drug-Eluting Stenting

  2010cites this paper
• Early and aggressive treatment of patients with ST-segment elevation myocardial infarction: deciphering recent clinical trials and the timing of optimal platelet inhibition

  2010cites this paper
• Acute coronary syndromes: assessing risk and choosing optimal pharmacological regimens for a superior outcome

  2010cites this paper
• Pharmacology in the Cardiac Catheterization Laboratory

  2010cites this paper
• Randomized, double‐blind comparison of effects of abiciximab bolus only vs. on‐label regimen on ex vivo inhibition of platelet aggregation in responders to clopidogrel undergoing coronary stenting

  2010cites this paper